Jinhua Wu

NEUROPHARMACOLOGY | Assistant Member
Phone: (772) 345-4716 | Fax: (772) 345-3649 |
Jinhua Wu

Dr. Wu is an expert in molecular biology, neurobehavioral pharmacology and in vitro pharmacology, particularly in assay development and library screening. His current research mainly focuses on the identification of novel smoking cessation medications using the nicotinic acetylcholine receptor as a drug target. He is also pursuing therapeutics for acute and chronic pain, utilizing a unique functional assay he developed for opioid receptors.

NEUROPHARMACOLOGY | Assistant Member
Phone: (772) 345-4716 | Fax: (772) 345-3649 |
Jinhua Wu

Dr. Wu is an expert in molecular biology, neurobehavioral pharmacology and in vitro pharmacology, particularly in assay development and library screening. His current research mainly focuses on the identification of novel smoking cessation medications using the nicotinic acetylcholine receptor as a drug target. He is also pursuing therapeutics for acute and chronic pain, utilizing a unique functional assay he developed for opioid receptors.

Biography

Dr. Jinhua Wu obtained his Ph.D. degree in the department of Biomedical Science, Integrative Biology PhD program at Florida Atlantic University in 2008. As a research fellow, he first trained in the laboratories of Dr. Doo-Sup Choi (2008~2010) and Dr. Gianrico Farrugia (2010~2011) at Mayo Clinic, Rochester, Minnesota. Dr. Wu subsequently moved back to Florida and continued his postdoctoral training with Dr. Lawrence Toll in Neuropharmacology at Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida. In 2014, Dr. Wu joined Assuage Pharmaceuticals, Inc. as Director of Pharmacology in Port St. Lucie, Florida, and later he was also promoted as a Senior Scientist then Assistant Member at Torrey Pines Institute for Molecular Studies, Florida. As a Principal Investigator, he has been awarded with several NIH-funded research grants for the development of novel smoking cessation medications since 2014. Dr. Wu’s research work has been published in over twenty internationally outstanding journals including Journal of Medicinal Chemistry, Neuropharmacology, British Journal of Pharmacology, Psychopharmacology, Journal of Neuroscience, and Biological Psychiatry. Dr. Wu is internationally recognized in the field of neuropharmacology.

Education

  • 1994~1998: Bachelor of Science in Biopharmaceuticals – Nanjing University and China Pharmaceutical University (1996~1998), Nanjing, P.R. China
  • 2000~2003: Master of Science in Biochemistry and Molecular Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
  • 2003~2008: Ph.D. in Biomedical Science, Florida Atlantic University
  • 2008~2010: Research Fellow with Dr. Doo-Sup Choi, Mayo Clinic, Rochester, MN
  • 2010~2011: Research Fellow with Dr. Gianrico Farrugia, Mayo Clinic, Rochester, MN
  • 2011~2014: Postdoctoral Fellow with Lawrence R. Toll, Torrey Pines Institute for Molecular Studies

Positions

  • 2016~present: Assistant Member, Neuropharmacology Program, Torrey Pines Institute for Molecular Studies
  • 2015~present: Affiliate Research Assistant Professor, CMBB, Charles Schmidt College of Science, Florida Atlantic University
  • 2013~present : Director of Pharmacology, Assuage Pharmaceuticals, Inc
  • 2014~2016: Senior Scientist, Neuropharmacology, Torrey Pines Institute for Molecular Studies
  • 2008~2008: Web Staff, Department of Chemistry, Florida Atlantic University
  • 2003~2008: Teaching Assistant/Research Assistant, Department of Biological Science/Biomedical Science, College of Science, Florida Atlantic University
  • 1998~2000: Lecturer, Department of Marine Biotechnology, Yancheng Institute of Technology, Jiangsu, P. R. China

Professional Affiliations

  • 2008~present: Membership, Neuroscience for Society
  • 2009~2013: Membership, American Chemistry Society
  • 2009~2013: Membership, American Association for the Advancement of Science (AAAS)

Research Focus

  • Molecular biology and pharmacology of nicotinic acetylcholine and opioid receptors
  • Development of novel medications for smoking cessation and the treatment for acute and chronic pain
  • Discovery of novel drugs from the TPIMS’ combinatorial compound libraries for potential drug targets
  • Assay development and translational research for other GPCRs and ligand-gated ion channels

Selected Publications

Selected Publications (10 of 23)

  1. Wu J, Zou H, Strong JA, Yu J, Zhou X, Xie Q, Zhao G, Jin M, Yu L. Bimodal effects of MK~801 on locomotion and stereotypy in C57BL/6 mice.Psychopharmacology (Berl). 2005 Jan;177(3):256~63. Epub 2004 Jul 28. PubMed PMID:15290006.
  2. Wu J, Li Z. Human polynucleotide phosphorylase reduces oxidative RNA damage and protects HeLa cell against oxidative stress. Biochem Biophys Res Commun. 2008 Jul 25; 372(2):288~92. doi: 10.1016/j.bbrc.2008.05.058. Epub 2008 May 21. PubMed PMID: 18501193; PubMed Central PMCID: PMC2531134
  3. Wu J, Jiang Z, Liu M, Gong X, Wu S, Burns CM, Li Z. Polynucleotide phosphorylase protects Escherichia coli against oxidative stress. Biochemistry. 2009 Mar 10;48(9):2012~20. doi: 10.1021/bi801752p. PubMed PMID: 19219992; PubMed Central PMCID: PMC2697445
  4. Wu J, Lee MR, Choi S, Kim T, Choi DS. ENT1 regulates ethanol~sensitive EAAT2 expression and function in astrocytes. Alcohol Clin Exp Res. 2010 Jun;34(6):1110~7. doi: 10.1111/j.1530~0277.2010.01187.x. Epub 2010 Apr 5. PubMed PMID: 20374202; PubMed Central PMCID: PMC2913860
  5. Patkar KA, Wu J, Ganno ML, Singh HD, Ross NC, Rasakham K, Toll L, McLaughlin JP. Physical presence of nor~binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long~lasting antagonistic effect on κ~opioid receptors. J Pharmacol Exp Ther. 2013 Sep; 346(3):545~54. doi:10.1124/jpet.113.206086. Epub 2013 Jul 12. PubMed PMID: 23853171
  6. Wu J, Perry DC, Bupp JE, Jiang F, Polgar WE, Toll L, Zaveri NT. [(125)I]AT~1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors. Neuropharmacology. 2013 Oct 3;77 C:193~199.doi:10.1016/j.neuropharm. 2013.09.023. [Epub ahead of print] PubMed PMID: 24095990
  7. Wu J, Zhang Y, Maida LE, Santos RG, Welmaker GS, LaVoi TM, Yu Y, Houghtena RA, Toll L and Giulianotti MA. Scaffold ranking and positional scanning utilized in the discovery of nAChR~selective compounds suitable for optimization studies. Journal of Medicinal Chemistry. 2013 DOI: 10.1021/jm401543h published online November 25, 2013
  8. Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015 Jan;172(2):668-80. doi: 10.1111/bph.12796. Epub 2014 Nov 5. PubMed PMID: 24903063; PubMed Central PMCID: PMC4292977
  9. Cippitelli A, Wu J (Co-first Author), Gaiolini KA, Mercatelli D, Schoch J, Gorman M, Ramirez A, Ciccocioppo R, Khroyan TV, Yasuda D, Zaveri NT, Pascual C, Xie XS, Toll L.AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45. doi: 10.1111/bph.13034. Epub 2015 Jan 23. PubMed PMID: 25440006; PubMed Central PMCID: PMC4376460
  10. Li Y, Cazares M, Wu J, Houghten RA, Toll L, Dooley C. Potent μ-Opioid Receptor Agonists from Cyclic Peptides Tyr-c[D-Lys-Xxx-Tyr-Gly]: Synthesis, Biological, and Structural Evaluation. J Med Chem. 2016 Feb 11;59(3):1239-45. doi:10.1021/acs.jmedchem.5b01899. Epub 2016 Jan 29. PubMed PMID: 26789491

Patents

  1. Meilei Jin, Hong Zou, Jinhua Wu, and GuoPing Zhao. Schizophrenia Animal Model and Platform for Screening Anti~ Schizophrenic Compounds. China Issuing No. : CN1470235; Issuing Date: 2004.01.28
  2. Marc Giulianotti, Lawrence Toll, Greg Welmaker, Jinhua Wu, Yongping Yu. Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation. provisional patent filed

Honors & Awards

Honors & Awards

  • 2017: INRC Travel Award
  • 2016~2017: Awardee of the NIH Commercialization Accelerator Program (CAP)
  • 2016: Awardee of NIH Innovation BioZone
  • 2004~2005: Winner of Marla Kace Siegel Memorial Scholarship in Recognition of Outstanding Academic Performance
  • 2002~2003: Winner of Presidential Fellowship for Excellence in Academic Performance, CAS
  • 2000~2003: Graduate Fellowship, Chinese Academy of Sciences